SpinChip Diagnostics
Acquisition in 2025
SpinChip Diagnostics AS is a Norwegian company founded in 2012, specializing in the development of point-of-care diagnostic systems utilizing lab-on-a-chip technology. Based in Oslo, the company focuses on diagnosing cardiovascular, endocrine, anemic, diabetic, infectious, and inflammatory diseases. SpinChip is set to introduce a state-of-the-art platform for in vitro diagnostic analyses that promises faster, easier, and more reliable results in both hospital and decentralized medical settings. The fully automated device can analyze blood samples within minutes, initially targeting the rapid cardiac segment with a Troponin-I analysis, with plans to expand to a comprehensive cardiac panel. The SpinChip platform aims to match the quality of high-sensitivity central laboratory analyzers, presenting a compelling value proposition compared to existing point-of-care solutions.
Oxford Nanopore Technologies
Post in 2023
Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.
Proxim Diagnostics
Corporate Round in 2023
Proxim Diagnostics Corp. specializes in the development and manufacture of handheld immunodiagnostic devices. Founded in 2009 and based in Mountain View, California, the company produces analyzers and disposable test cartridges capable of conducting crucial laboratory tests on whole blood. These tests measure blood gases, electrolytes, metabolites, as well as infectious disease antigens and antibodies. Proxim's innovative devices are designed for various applications, including emergency medical response, intensive care units, nursing settings, home care, and rural clinics. With a focus on maintaining high sensitivity and precision while keeping manufacturing costs low, Proxim Diagnostics aims to facilitate rapid testing and early treatment for patients, making its products suitable for both domestic and international markets.
InDevR, Inc. is a biotechnology company based in Boulder, Colorado, specializing in the development and marketing of life science instrumentation and assay products focused on the analysis of viruses and microorganisms. Established in 2002, InDevR offers a range of innovative technologies, including the Virus Counter for virus quantification, the FluChip for rapid pathogen detection, and the ViroPrep Allantoic Influenza sample cleanup kit. The company also provides the miPLEX system for multiplexed immunoassays, the Vidia fluorescence microarray imaging system, and the ampliPHOX Reader for photo-polymerization activation on microarrays. InDevR's products are designed to enhance vaccine characterization and facilitate the research, development, and manufacturing of vaccines, particularly in tracking seasonal and emerging influenza viruses.
Accunome
Private Equity Round in 2022
Accunome is a developer of molecular diagnostic technology that focuses on the research and development of diagnostic instruments and detection reagents. The company specializes in providing testing solutions for severe infectious diseases, enhancing diagnostic efficiency while aiming to reduce costs for its clients. Accunome's flagship platform, DXcellence12, has received state food and drug registration, as well as EU CE certification, further validating its commitment to high-quality diagnostic solutions. Additionally, the company offers a combined detection kit for influenza A/B and respiratory syncytial virus nucleic acid, which has also achieved EU CE certification. This positions Accunome as a key player in the molecular diagnostics field, aiming to improve healthcare outcomes through advanced technology.
Specific Diagnostics
Acquisition in 2022
Specific Diagnostics LLC, established in 2011 and based in West Palm Beach, Florida, specializes in developing innovative solutions for bacterial detection, identification, and antibiotic susceptibility testing. The company's flagship product is the Specific Reveal system, which employs patented small molecule sensor technology to deliver rapid and cost-effective antibiotic susceptibility results, enabling clinics to tailor treatments more efficiently.
Accellix, Inc. is a biotechnology company specializing in the development of microflow cytometer systems for diagnostic applications. Founded in 2009 and headquartered in San Jose, California, with an additional office in Jerusalem, the company creates compact, table-top flow cytometry instruments that utilize microfluidics technology. These instruments are designed for point-of-care testing and include disposable, single-use cartridges tailored for specific tests. Accellix's products enable rapid and accurate diagnostic results, particularly for applications such as early detection and monitoring of blood infections, as well as HIV/AIDS. The company's innovative platform also supports quality control requirements for cell and gene therapy, offering automated sample preparation that enhances reproducibility and accuracy in laboratory settings.
Invisible Sentinel
Acquisition in 2019
Invisible Sentinel Inc. is a biotechnology company based in Philadelphia, Pennsylvania, that specializes in microbial detection tools for various industries, including food safety, healthcare, and environmental testing. Founded in 2006, the company develops innovative diagnostic technologies, particularly its Veriflow test kits, which are designed to detect common food and beverage pathogens such as salmonella, listeria, and E. coli, as well as spoilage organisms. These kits enable rapid, on-site analysis, significantly reducing the time required for sample preparation. The company also offers specialized test kits for winemakers and brewers, providing same-day results for spoilage organisms that can impact product quality. Invisible Sentinel's technologies are aimed at improving food safety and preventing foodborne illnesses, setting a new standard for quality control in the food distribution network. As of 2019, the company operates as a subsidiary of bioMérieux S.A.
Suzhou Hybiome Biomedical Engineering
Acquisition in 2018
Suzhou Hybiome Biomedical Engineering Co., Ltd., established in 2009 and headquartered in Suzhou, China, specializes in the research, manufacturing, and sales of instruments and matching reagents for clinical immunological analysis and blood tests. Its product portfolio includes automatic luminescence immunity analyzers with corresponding immunoassay reagents, and automatic blood grouping analyzers suitable for micro-column gel immunoassay. As a subsidiary of bioMérieux S.A., Hybiome's solutions aim to facilitate reliable, efficient, and accurate diagnosis in medical care settings.
Astute Medical
Acquisition in 2018
Astute Medical, Inc. is a life science tools company focused on improving the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers. Founded in 2007 and based in San Diego, California, with an additional location in Paris, France, the company specializes in creating novel diagnostic tests that enable rapid diagnosis and risk assessment for conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Astute Medical's flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers associated with acute kidney injury, while the Astute140 meter converts the test's fluorescent signal into a single numerical result. The company markets its products primarily in the United States and Europe and operates as a subsidiary of bioMérieux S.A.
Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.
Hyglos
Acquisition in 2016
Hyglos GmbH is a German biotechnology company established in 2000, currently operating as a subsidiary of bioMérieux S.A. It specializes in the development of highly specific bacteriophage-derived proteins for improved detection and removal of harmful bacteria and their toxins, such as Lipopolysaccharides (LPS). Hyglos offers a range of products including endotoxin detection kits, endotoxin removal kits, and diagnostic tests for food safety testing, human diagnostics, and antimicrobial applications. Its customer base comprises universities, research institutes, diagnostic companies, biotech companies, food safety testing laboratories, and pharmaceutical companies worldwide. The company's technology enables the production of molecules for effective binding and lysis of bacteria, exploiting the principles of bacteriophage biology. Hyglos' products are sold through distributors globally.
Applied Maths
Acquisition in 2016
Applied Maths is a company specializing in the development of professional bioinformatics applications and services tailored for the biosciences industry. It focuses on creating software products that facilitate the databasing, analysis, and interpretation of complex biological data. With an emphasis on data integration and platform technology, Applied Maths provides essential tools that support researchers and professionals in effectively managing and utilizing biological information. Its offerings aim to enhance the understanding of biological systems through innovative technological solutions.
SARL ADVENCIS
Acquisition in 2014
SARL ADVENCIS is a privately held company that manufactures lab instruments and medical devices.
BioFire Diagnostics
Acquisition in 2013
BioFire Diagnostics is a clinical diagnostics company based in Salt Lake City, Utah, that focuses on detecting pathogens and mutations for molecular diagnostics. Founded in 1990, the company holds over 70 patents related to polymerase chain reaction (PCR) technology, including innovations in rapid PCR cycling. BioFire offers nearly 200 products tailored for clinical, research, and military applications. Its services are designed to provide accurate results in syndromic infectious disease diagnostics, utilizing real-time thermocycling and mutation scanning. BioFire's diagnostic panels test for a wide range of viruses, bacteria, and antimicrobial resistance genes, thereby enabling healthcare providers to assess and improve treatment outcomes for patients of all ages.
Quanterix
Series C in 2012
Quanterix Corporation is a life sciences company focused on developing an ultra-sensitive digital immunoassay platform to advance precision health in diagnostics and research. Their proprietary technology, Simoa, enables the detection of protein biomarkers at very low concentrations in biological samples such as blood and serum, which are often undetectable using traditional methods. This high level of sensitivity allows for earlier disease detection, improved prognosis, and more precise treatment methods. Quanterix's platforms include bead-based and planar array systems designed to provide reliable and robust assay performance, addressing various unmet medical needs in clinical diagnostics, drug development, and life science research.
RTS Life Sciences
Acquisition in 2012
RTS Life Sciences Ltd. manufactures and provides automated products and solutions for industrial and scientific applications.
RAS Lifesciences
Acquisition in 2012
RAS Lifesciences is a manufacturer of diagnostic kits located in Muluga, India. The company specializes in the development and manufacturing of products related to molecular biology. Its primary focus is on creating innovative solutions for diagnostic applications, leveraging advanced technologies in the field of molecular biology to enhance healthcare outcomes.
Argene SA
Acquisition in 2011
Argene SA is a specialising in molecular diagnostics for immunocompromised patients.
AES Chemunex
Acquisition in 2011
AES Laboratoire has products spanning applications for the food, pharmaceutical, and cosmetic industries. The company’s offerings include a complete portfolio of conventional and novel culture media, rapid microbiology testing methods, and laboratory instruments, as well as cytometry for the detection of microorganisms, with an innovative range of flow cytometers and a solid-phase cytometer, ChemScan RDI. The company also provides a range of services, as well as software for laboratory monitoring and metrology.
Shanghai Zenka Biotechnology
Acquisition in 2010
Shanghai Zenka Biotechnology is a biotechnology company.
Meikang Biotech
Acquisition in 2010
Meikang Biotech is a manufacturer of medical rapid test products specializing in lateral flow immunoassay technology. The company provides a diverse array of rapid tests that target infectious diseases, cardiovascular diseases, and cancer. Many of its products are CE marked, and several have obtained FDA 510(k) approval, demonstrating their adherence to international regulatory standards. This positions Meikang Biotech as a significant player in the medical diagnostics field, contributing to timely and effective disease detection and management.
PML Microbiologicals
Acquisition in 2008
PML Microbiologicals, Inc. is a manufacturer of culture media and microbiological products serving clinical and industrial markets in North America. Established in 1969 and headquartered in Wilsonville, Oregon, the company produces a wide range of products, including prepared culture media, stains, reagents, quality control organisms, and sterility products. Its offerings also encompass custom solutions such as minimum inhibitory concentration panels, parasitology kits, diluents, and rinsing fluids, catering to various industries, including clinical, pharmaceutical, research, environmental, personal care, and food and beverage. PML Microbiologicals operates manufacturing facilities in Mississauga, Canada, and Portland, Oregon, and functions as a subsidiary of BioMérieux S.A.
AviaraDx
Acquisition in 2008
AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient’s tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will eventually provide information critical to predict treatment response to a given therapeutic regimen. AviaraDx offers diagnostic tests to qualified physicians or laboratories through its certified CLIA and CAP laboratory service operations. The company's first two diagnostic test offerings are based on its proprietary technologies used in molecular classification of metastatic cancer (CancerTYPE ID™) and its test to assess risk of recurrence in certain breast cancer patients, (H/I™ (HOXB13/IL17BR).
AB bioMérieux
Acquisition in 2008
AB bioMérieux is a privately held company that designs, develops, produces, and markets diagnosis systems for medical applications.
AdvanDx, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in molecular diagnostic tests for identifying pathogens responsible for critical infections in hospitalized patients. Founded in 2002, the company focuses on enhancing the speed and accuracy of pathogen identification through innovative testing methods. Its product offerings include QuickFISH and PNA FISH tests, which allow for the direct identification of bacteria and yeast from positive blood cultures, as well as XpressFISH, a platform designed to detect resistance markers. Additionally, AdvanDx provides PNA Probes for ribosomal RNA sequences and various accessories to support its testing systems. The company's products are distributed through a network of sales representatives and partners across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. AdvanDx aims to improve patient outcomes by enabling healthcare providers to optimize antibiotic therapy while reducing unnecessary antibiotic use and hospital costs. As of July 2015, AdvanDx operates as a subsidiary of OpGen, Inc.
BTF Pty
Acquisition in 2007
BTF Pty is a manufacturer and supplier specializing in precise quality controls for Cryptosporidium and Giardia testing, essential for ensuring safe drinking water. The company also produces quantitative biological reference materials and standards tailored for the life sciences sector. These reference samples are utilized by analytical laboratories to enhance the quality control processes of their testing, thereby supporting public health and safety.
Biomedics
Acquisition in 2007
Biomedics is a specialized technical laboratory in elaboration of prepared culture and diagnostic media.
Bacterial Barcodes
Acquisition in 2006
Bacterial Barcodes provides the equipment, reagents and software for microbial genotyping of bacteria and fungi. Packaged together, these components are referred to as the DiversiLab System.
MEDoctor
Seed Round in 2000
MEDoctor, established in 2017, specializes in an AI-driven health assessment system that helps users identify potential health issues based on their symptoms. Its Symptom Checker, accessible worldwide and free of charge, covers nearly 1000 diseases, ranging from common ailments like colds to serious conditions such as cancer. The system, user-friendly and accessible on any web-enabled device, guides users towards appropriate healthcare professionals. MEDoctor's technology has evolved from legacy systems targeting hospitals and HMOs, transitioning to a cloud-based platform suitable for individual patients using smartphones.